Fact based stock research
Jointown Pharmaceutical (SHSE:600998)

CNE100000W45

Jointown Pharmaceutical stock research in summary

Jointown Pharmaceutical shares are less expensive than other comparable stocks. They are safely financed, show above average growth and are good value. We recommend evaluating whether the future of the company Jointown Pharmaceutical is really as difficult as the low price of the stock suggests. If you believe that the future of the company is market-typical or even better, then this could be an argument for a share purchase.

Latest Obermatt Ranks


Value Rank	73
Growth Rank	86
Safety Rank	89
Combined Rank	96

Country	China
Industry	Health Care Distributors
Index	SSE Composite
Size class	XX-Large

June 26, 2020. Stock data may be delayed. Login to get the most recent research.

Add to Watchlist

Filter Similar Stocks

Similar Top 10

Google: Jointown Pharmaceutical

News	Videos
Wikipedia about Jointown Pharmaceutical	Management
Employee Satisfaction	Customer Satisfaction

Research History: Jointown Pharmaceutical

RESEARCH HISTORY	2017	2018	2019	2020
VALUE
VALUE	52	74	73	73
GROWTH
GROWTH	93	46	61	86
SAFETY
SAFETY	58	62	59	89
COMBINED
COMBINED	80	69	83	96

Last update of Combined Rank: 26-Jun-2020. Financial reporting date used for calculating ranks: 31-Mar-2020. Stock research history is based on the Obermatt Method. The higher the rank, the better Jointown Pharmaceutical is in the corresponding investment strategy.

Value Metrics in Detail

VALUE METRICS	2017	2018	2019	2020
PRICE VS. REVENUES (P/S)
PRICE VS. REVENUES (P/S)	87	86	91	81
PRICE VS. PROFITS (P/E)
PRICE VS. PROFITS (P/E)	35	54	67	71
PRICE VS. CAPITAL (Market-to-Book)
PRICE VS. CAPITAL (Market-to-Book)	60	68	78	65
DIVIDEND YIELD
DIVIDEND YIELD	1	42	28	36
CONSOLIDATED RANK: VALUE
CONSOLIDATED RANK: VALUE	52	74	73	73

Last update of Value Rank: 26-Jun-2020. Stock analysis on value ratios: The higher the rank, the lower the value ratio of Jointown Pharmaceutical; except for dividend yield where the rank is higher, the higher the yield.

Growth Metrics in Detail

GROWTH METRICS	2017	2018	2019	2020
REVENUE GROWTH
REVENUE GROWTH	93	42	70	70
PROFIT GROWTH
PROFIT GROWTH	63	80	56	86
STOCK RETURNS
STOCK RETURNS	60	26	40	59
CONSOLIDATED RANK: GROWTH
CONSOLIDATED RANK: GROWTH	93	46	61	86

Last update of Growth Rank: 31-Mar-2020. Stock analysis on growth metrics: The higher the rank, the higher the growth and returns of Jointown Pharmaceutical.

Safety Metrics in Detail

SAFETY METRICS	2017	2018	2019	2020
LEVERAGE
LEVERAGE	30	38	30	43
REFINANCING
REFINANCING	87	96	98	98
LIQUIDITY
LIQUIDITY	13	38	41	64
CONSOLIDATED RANK: SAFETY
CONSOLIDATED RANK: SAFETY	58	62	59	89

Last update of Safety Rank: 19-Jun-2020. Stock analysis on safety metrics: The higher the rank, the lower the leverage of Jointown Pharmaceutical and the more cash is available to service its debt.

Stock analysis by the purely financial fact-based Obermatt Method for the investment strategies Value, Growth and Safety for Jointown Pharmaceutical from June 26, 2020.

We invest in our stock tips ourselves and openly publish the returns of our portfolio. That's how much we believe in our stock research. Subscribe to the top 10 stocks for 100 markets conveniently by e-mail.